nivolumab,ipilimumab,cabozantinib
bms
[' ipi ', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo', 'cosmic-313']
#gu23 terrific talk from on subgroups from #cosmic313
- pfs benefit of triplet maintained hr 0.74 in all pts and 0.68 in intermediate
follow-up for os ongoing 
GU Oncologist/Clinical Trials/ Experimental Therapeutics @UCD_Cancer @UCDavisHealth via @uofcincy @GoBEARCATS. Tweets= My opinions #RCC #ASCO #immunotherapy